AI in Biotechnology Market by Function (Drug Design & Optimization, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply Chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events) and End User - Global Forecast to 2035
The global AI in biotechnology market is projected to reach USD 22,716.5 million by 2035 from USD 4,156.9 million in 2025, at a high CAGR of 18.5% during the forecast period. The market is progressing steadily, driven by the growing adoption of AI for predictive analytics in drug safety and efficacy, the increasing use of AI-powered automation in laboratory processes, and the rising demand for cost-efficient and accelerated research pipelines. Moreover, the expanding availability of large-scale biological datasets, advancements in cloud computing infrastructure, and supportive government initiatives promoting AI in life sciences further propel market growth. The convergence of AI with emerging biotechnologies is enabling faster innovation, improved decision-making, and more personalized healthcare solutions.
“The research & development segment of the AI in biotechnology market is the largest segment during the forecast period.”
Based on function, the research & development (R&D) segment accounted for the largest share of the AI in biotechnology market and is projected to maintain its lead in the coming years. This dominance is driven by the increasing use of AI to accelerate drug discovery, optimize molecular design, and predict compound efficacy and safety. AI-powered tools enable researchers to analyze large-scale genomic, proteomic, and clinical datasets more efficiently, reducing experimental timelines and costs. Additionally, the integration of machine learning algorithms with high-throughput screening and automated laboratory platforms is enhancing the precision and scalability of R&D processes. As biotech companies strive to bring novel therapeutics to market faster, the adoption of AI in R&D continues to be a key growth driver.
“Based on the end user, the pharmaceutical companies segment accounted for the largest share of AI in biotechnology market during the forecast period.”
The pharmaceutical companies segment accounted for the largest share of the AI in biotechnology market during the forecast period. This growth is driven by the increasing adoption of AI for accelerating drug discovery, optimizing clinical trial design, and predicting drug efficacy and safety profiles. Pharmaceutical firms are leveraging AI to analyze large-scale biological and clinical datasets, identify novel drug targets, and streamline R&D workflows, reducing time and cost. Additionally, AI-enabled predictive modeling and virtual screening tools help companies make data-driven decisions, enhance success rates, and bring new therapies to market more efficiently. The rising demand for personalized medicine and the pressure to innovate rapidly further reinforce the adoption of AI within the pharmaceutical sector.
“Asia Pacific is projected to witness the highest growth rate during the forecast period.”
The Asia Pacific region is projected to witness the highest growth rate in the AI in biotechnology market during the forecast period. This rapid expansion is driven by a strong focus on technological advancement and research excellence. Countries across the region are strengthening their innovation ecosystems through enhanced infrastructure, academic-industry partnerships, and cross-border collaborations. The growing emphasis on precision medicine, data-driven healthcare, and sustainable biomanufacturing is also creating new opportunities for market development. Moreover, supportive regulatory frameworks and increasing public-private initiatives position Asia Pacific as a global hub for next-generation biotechnological progress.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the AI in biotechnology marketplace. The breakdown of primary participants is as mentioned below:
The key players operating in the AI in biotechnology market include NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schr?dinger, Inc. (US), BenevolentAI (UK), Data4Cure, Inc. (US), Qiagen (Germany), Insilico Medicine (US), DNAnexus, Inc. (US), Tempus (US), SOPHiA GENETIC (Switzerland), Predictive Oncology (US), Deep Genomics (Canada), NuMedii, Inc. (US), XtalPi Inc. (China), Iktos (France), BPGbio, Inc. (US), Eurofins Discovery (US), VeriSIM Life (US), Lifebit (UK), Verge Genomics (US), Logica (US), American Chemical Society (US), and Aganitha AI Inc. (India).
Research Coverage
The report analyzes the AI in biotechnology market and aims to estimate the market size and future growth potential of various market segments, based on offering, function, deployment mode, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will benefit established firms as well as new entrants and smaller firms in gauging the market pulse, which in turn will help them capture a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights into the following:
“The research & development segment of the AI in biotechnology market is the largest segment during the forecast period.”
Based on function, the research & development (R&D) segment accounted for the largest share of the AI in biotechnology market and is projected to maintain its lead in the coming years. This dominance is driven by the increasing use of AI to accelerate drug discovery, optimize molecular design, and predict compound efficacy and safety. AI-powered tools enable researchers to analyze large-scale genomic, proteomic, and clinical datasets more efficiently, reducing experimental timelines and costs. Additionally, the integration of machine learning algorithms with high-throughput screening and automated laboratory platforms is enhancing the precision and scalability of R&D processes. As biotech companies strive to bring novel therapeutics to market faster, the adoption of AI in R&D continues to be a key growth driver.
“Based on the end user, the pharmaceutical companies segment accounted for the largest share of AI in biotechnology market during the forecast period.”
The pharmaceutical companies segment accounted for the largest share of the AI in biotechnology market during the forecast period. This growth is driven by the increasing adoption of AI for accelerating drug discovery, optimizing clinical trial design, and predicting drug efficacy and safety profiles. Pharmaceutical firms are leveraging AI to analyze large-scale biological and clinical datasets, identify novel drug targets, and streamline R&D workflows, reducing time and cost. Additionally, AI-enabled predictive modeling and virtual screening tools help companies make data-driven decisions, enhance success rates, and bring new therapies to market more efficiently. The rising demand for personalized medicine and the pressure to innovate rapidly further reinforce the adoption of AI within the pharmaceutical sector.
“Asia Pacific is projected to witness the highest growth rate during the forecast period.”
The Asia Pacific region is projected to witness the highest growth rate in the AI in biotechnology market during the forecast period. This rapid expansion is driven by a strong focus on technological advancement and research excellence. Countries across the region are strengthening their innovation ecosystems through enhanced infrastructure, academic-industry partnerships, and cross-border collaborations. The growing emphasis on precision medicine, data-driven healthcare, and sustainable biomanufacturing is also creating new opportunities for market development. Moreover, supportive regulatory frameworks and increasing public-private initiatives position Asia Pacific as a global hub for next-generation biotechnological progress.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the AI in biotechnology marketplace. The breakdown of primary participants is as mentioned below:
- By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
- By Designation - C-Level: 35%, Director Level: 25%, and Others: 40%
- By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Latin America: 3%, Middle East & Africa: 2%
The key players operating in the AI in biotechnology market include NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schr?dinger, Inc. (US), BenevolentAI (UK), Data4Cure, Inc. (US), Qiagen (Germany), Insilico Medicine (US), DNAnexus, Inc. (US), Tempus (US), SOPHiA GENETIC (Switzerland), Predictive Oncology (US), Deep Genomics (Canada), NuMedii, Inc. (US), XtalPi Inc. (China), Iktos (France), BPGbio, Inc. (US), Eurofins Discovery (US), VeriSIM Life (US), Lifebit (UK), Verge Genomics (US), Logica (US), American Chemical Society (US), and Aganitha AI Inc. (India).
Research Coverage
The report analyzes the AI in biotechnology market and aims to estimate the market size and future growth potential of various market segments, based on offering, function, deployment mode, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will benefit established firms as well as new entrants and smaller firms in gauging the market pulse, which in turn will help them capture a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights into the following:
- Analysis of key drivers (growing cross-industry collaborations and partnerships, growing need to reduce time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth) challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in biotechnology market
- Market Development: Comprehensive information on the lucrative emerging markets, offering, function, deployment mode, end user, and region
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market, like NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schr?dinger Inc. (US), and BenevolentAI (UK)
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW
4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION
4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING AND COUNTRY
4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT
4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing cross-industry collaborations and partnerships
5.2.1.2 Increasing need to reduce time and cost of drug discovery & development
5.2.1.3 Rising adoption of AI in precision medicine
5.2.1.4 Increasing investments in semiconductor chipsets
5.2.2 RESTRAINTS
5.2.2.1 High implementation costs
5.2.2.2 Data privacy risks and compliance challenges
5.2.3 OPPORTUNITIES
5.2.3.1 Rise of advanced analytics and predictive modeling
5.2.3.2 Surge in biotechnology investments
5.2.3.3 Innovations across healthcare, agriculture, and environmental science
5.2.4 CHALLENGES
5.2.4.1 Data quality and interpretability issues
5.2.4.2 Shortage of qualified experts and evolving regulatory challenges
5.3 UNMET NEEDS AND WHITE SPACES
5.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
5.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
6 INDUSTRY TRENDS
6.1 EVOLUTION OF AI IN BIOTECHNOLOGY
6.2 PORTER’S FIVE FORCES ANALYSIS
6.2.1 BARGAINING POWER OF SUPPLIERS
6.2.2 BARGAINING POWER OF BUYERS
6.2.3 THREAT OF SUBSTITUTES
6.2.4 THREAT OF NEW ENTRANTS
6.2.5 INTENSITY OF COMPETITIVE RIVALRY
6.3 MACROECONOMICS INDICATORS
6.3.1 INTRODUCTION
6.3.2 GDP TRENDS AND FORECAST
6.3.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
6.4 VALUE CHAIN ANALYSIS
6.5 ECOSYSTEM ANALYSIS
6.6 PRICING ANALYSIS
6.6.1 INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY OFFERING, BY KEY PLAYERS (2024)
6.6.2 INDICATIVE PRICING OF AI IN BIOTECHNOLOGY, BY REGION
6.7 KEY CONFERENCES AND EVENTS, 2025–2026
6.8 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6.9 INVESTMENT AND FUNDING SCENARIO
6.10 CASE STUDY ANALYSIS
6.10.1 CASE STUDY 1: RAPID TRAINING OF PROTEIN MODELS USING NVIDIA DGX CLOUD
6.10.2 CASE STUDY 2: IMPROVED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION
6.10.3 CASE STUDY 3: ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS
6.11 IMPACT OF 2025 US TARIFF ON AI IN BIOTECHNOLOGY MARKET
6.11.1 INTRODUCTION
6.11.2 KEY TARIFF RATES
6.11.3 PRICE IMPACT ANALYSIS
6.11.4 IMPACT ON COUNTRIES/REGIONS
6.11.4.1 North America
6.11.4.2 Europe
6.11.4.3 Asia Pacific
6.11.5 IMPACT ON END-USE INDUSTRIES
6.11.5.1 Pharmaceutical companies
6.11.5.2 Biotechnology companies
6.11.5.3 Research institutes and labs
6.11.5.4 Healthcare providers
6.11.5.5 Contract Research Organizations (CROs)
7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS
7.1 KEY EMERGING TECHNOLOGIES
7.1.1 NATURAL LANGUAGE PROCESSING (NLP)
7.1.2 PREDICTIVE ANALYTICS
7.2 COMPLEMENTARY TECHNOLOGIES
7.2.1 CLOUD COMPUTING
7.2.2 BIG DATA ANALYTICS
7.3 TECHNOLOGY/PRODUCT ROADMAP
7.4 PATENT ANALYSIS
7.4.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY
7.4.2 JURISDICTION AND TOP APPLICANT ANALYSIS
7.5 FUTURE APPLICATIONS
7.5.1 AI-ENABLED PRECISION DISCOVERY AND MULTI-OMICS INTEGRATION
7.5.2 GENERATIVE BIOLOGY AND AUTOMATED DESIGN OF MOLECULES, PROTEINS, AND GENETIC SYSTEMS
7.6 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET
7.6.1 INTRODUCTION
7.6.2 TOP USE CASES AND MARKET POTENTIAL
7.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
7.6.3.1 Drug discovery and development market
7.6.3.2 Genomics and bioinformatics market
7.6.3.3 Medical imaging & diagnostics market
7.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN AI IN BIOTECHNOLOGY MARKET
7.6.4.1 User readiness
7.6.4.1.1 Pharmaceutical companies
7.6.4.1.2 Biotechnology companies
7.6.4.2 Impact assessment
7.6.4.2.1 User A: Pharmaceutical companies
7.6.4.2.1.1 Implementation
7.6.4.2.1.2 Impact
7.6.4.2.2 User B: Biotechnology companies
7.6.4.2.2.1 Implementation
7.6.4.2.2.2 Impact
7.6.5 CASE STUDY ON AI/GENERATIVE AI IMPLEMENTATION
7.6.5.1 Case Study 1: Enhanced operations and revenue using AI-driven real-world data analytics
7.6.5.2 Case study 2: Advance AI-powered target discovery with proprietary AI platform
8 REGULATORY LANDSCAPE
8.1 REGIONAL REGULATIONS AND COMPLIANCE
8.1.1 NORTH AMERICA
8.1.2 EUROPE
8.1.3 ASIA PACIFIC
8.1.4 LATIN AMERICA
8.1.5 MIDDLE EAST & AFRICA
8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8.3 INDUSTRY STANDARDS
9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
9.1 DECISION-MAKING PROCESS
9.2 INFLUENCE OF STAKEHOLDERS AND BUYING CRITERIA
9.2.1 BUYING CRITERIA
9.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
9.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9.5 END-USER EXPECTATIONS
10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING
10.1 INTRODUCTION
10.2 END-TO-END SOLUTIONS
10.2.1 GROWING USE OF ADVANCED ALGORITHMS FOR BETTER PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH
10.3 NICHE SOLUTIONS
10.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION
10.4 TECHNOLOGIES
10.4.1 ADOPTION OF ADVANCED TECHNOLOGIES FOR DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH
10.5 SERVICES
10.5.1 CONSULTING SERVICES
10.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption
10.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
10.5.2.1 Increasing precision and efficiency in IT support services to boost demand
10.5.3 TRAINING & EDUCATION SERVICES
10.5.3.1 Need for skilled talent for better training & education services to drive market
10.5.4 POST-SALES & MAINTENANCE SERVICES
10.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market
11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION
11.1 INTRODUCTION
11.2 RESEARCH & DEVELOPMENT
11.2.1 DRUG DISCOVERY
11.2.1.1 Molecular design & optimization
11.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market
11.2.1.2 Biomarker discovery
11.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand
11.2.1.3 Structure-activity relationship (SAR) modeling
11.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth
11.2.2 CLINICAL DEVELOPMENT
11.2.2.1 Trial design
11.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market
11.2.2.2 Site selection
11.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth
11.2.2.3 Recruitment
11.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand
11.2.2.4 Clinical data assessment
11.2.2.4.1 Ability of clinical data assessment for efficient and accurate of data interpretation to propel market
11.2.2.5 Predictive toxicity & risk monitoring
11.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates
11.2.2.6 Monitoring & drug adherence
11.2.2.6.1 Enhanced patient compliance with monitoring and drug adherence to drive market
11.2.2.7 Real-world evidence (RWE) analysis
11.2.2.7.1 Enhanced safety monitoring and economic evaluation with RWE analysis to propel growth
11.3 REGULATORY COMPLIANCE
11.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH
11.4 MANUFACTURING & SUPPLY CHAIN
11.4.1 SUPPLY CHAIN PLANNING
11.4.1.1 Increasing demand for real-time data analytics to accelerate market growth
11.4.2 INVENTORY MANAGEMENT
11.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel market growth
11.4.3 LOGISTICS OPTIMIZATION
11.4.3.1 Ability of AI for increased collaboration and transparency in biotechnology logistics to aid growth
11.4.4 DEMAND FORECASTING
11.4.4.1 Ability to integrate data for a reliable demand forecast to fuel market growth
11.4.5 PREDICTIVE MAINTENANCE
11.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand
11.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS
11.5 LAUNCH & COMMERCIAL
11.5.1 LAUNCH COORDINATION
11.5.1.1 Increasing product launch success rates through predictive analytics to boost adoption
11.5.2 PATIENT ENGAGEMENT
11.5.2.1 Real-time patient feedback for better health outcomes to support growth
11.5.3 MARKETING OPERATIONS
11.5.3.1 Enhanced marketing performance with AI to boost market growth
11.5.4 PREDICTIVE PRICING
11.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption
11.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT
11.6.1 MEDICATION ADHERENCE
11.6.1.1 Growing demand for personalized treatment plans to drive market
11.6.2 ADVERSE EVENT REPORTING
11.6.2.1 Faster post-market surveillance and enhanced drug safety to drive demand
11.6.3 PATIENT MONITORING
11.6.3.1 Rise of remote healthcare solutions to boost market demand
11.6.4 COMPLIANCE MONITORING
11.6.4.1 Increasing complexity of regulatory requirements to drive adoption
11.6.5 PATIENT SUPPORT PROGRAMS
11.6.5.1 Growing interest in patient-centered care to support market growth
11.7 CORPORATE
11.7.1 RISK MANAGEMENT
11.7.1.1 Rising expenditure for drug development to support growth
11.7.2 COMPLIANCE MONITORING
11.7.2.1 Strict guidelines for complex regulatory landscapes to aid market growth
11.7.3 SALES FORCE OPTIMIZATION
11.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization
11.7.4 OTHER CORPORATE FUNCTIONS
12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE
12.1 INTRODUCTION
12.2 CLOUD-BASED SOLUTIONS
12.2.1 PUBLIC CLOUD
12.2.1.1 Need to reduce dependency on expensive on-premises infrastructure to boost demand
12.2.2 PRIVATE CLOUD
12.2.2.1 Need for enhanced security and data protection to propel market growth
12.2.3 MULTI-CLOUD
12.2.3.1 Enhanced flexibility and cost optimization to support market growth
12.2.4 HYBRID CLOUD
12.2.4.1 Cost efficiency and flexibility of hybrid cloud models to fuel market growth
12.3 ON-PREMISES SOLUTIONS
12.3.1 BETTER DATA SECURITY, PRIVACY, AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH
13 AI IN BIOTECHNOLOGY MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL COMPANIES
13.2.1 INNOVATION AND EFFICIENCY WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION
13.3 BIOTECHNOLOGY COMPANIES
13.3.1 ABILITY OF AI-DRIVEN INNOVATIONS FOR BETTER PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT MARKET GROWTH
13.4 RESEARCH INSTITUTES & LABS
13.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS
13.5 HEALTHCARE PROVIDERS
13.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION
13.6 CONTRACT RESEARCH ORGANIZATIONS
13.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH
14 AI IN BIOTECHNOLOGY MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 US to dominate North American AI in biotechnology market during study period
14.2.3 CANADA
14.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 GERMANY
14.3.2.1 Increased funding in startups to drive uptake of AI in biotechnology
14.3.3 UK
14.3.3.1 Increasing investments and government fund allocations to drive market
14.3.4 FRANCE
14.3.4.1 Government initiatives in France to support market growth
14.3.5 ITALY
14.3.5.1 Growing investments to create opportunities for market growth
14.3.6 SPAIN
14.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market
14.3.7 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 JAPAN
14.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive Japanese market
14.4.3 CHINA
14.4.3.1 Rising foreign investments in biotechnology and biopharmaceuticals to propel market growth
14.4.4 INDIA
14.4.4.1 Increasing number of startups and growing support from government to propel market growth
14.4.5 SOUTH KOREA
14.4.5.1 Significant advances in AI integration for R&D to fuel growth
14.4.6 AUSTRALIA
14.4.6.1 Accelerating AI adoption in Australia’s biotech sector to augment market growth
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Funding of biotech companies to drive Brazilian market growth
14.5.3 MEXICO
14.5.3.1 Investment inflows and strengthening AI-related education to spur market growth
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.2 GCC COUNTRIES
14.6.2.1 Increase in healthcare investments to support market growth
14.6.3 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET
15.3 REVENUE ANALYSIS, 2020–2024
15.4 MARKET SHARE ANALYSIS, 2024
15.4.1 RANKING OF KEY MARKET PLAYERS
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Component footprint
15.5.5.4 Function footprint
15.5.5.5 End-user footprint
15.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SME players
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & UPGRADES
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 NVIDIA CORPORATION
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 ILLUMINA, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 RECURSION
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.3.4 Other developments
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 SCHR?DINGER, INC.
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product upgrades
16.1.4.3.2 Deals
16.1.4.3.3 Other developments
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 BENEVOLENTAI
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Deals
16.1.5.3.2 Other developments
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 DATA4CURE, INC.
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Deals
16.1.7 QIAGEN
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches and enhancements
16.1.7.3.2 Deals
16.1.8 INSILICO MEDICINE
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product launches, approvals, and enhancements
16.1.8.3.2 Deals
16.1.8.3.3 Other developments
16.1.9 DNANEXUS, INC.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Deals
16.1.9.3.2 Other developments
16.1.10 TEMPUS
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product approvals
16.1.10.3.2 Deals
16.1.10.3.3 Other developments
16.1.11 SOPHIA GENETICS
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches
16.1.11.3.2 Deals
16.1.11.3.3 Other developments
16.1.12 PREDICTIVE ONCOLOGY
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches
16.1.12.3.2 Deals
16.1.12.3.3 Expansions
16.1.13 DEEP GENOMICS
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Product launches
16.1.14 NUMEDII, INC.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.15 XTALPI INC.
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Deals
16.1.16 IKTOS
16.1.16.1 Business overview
16.1.16.2 Products offered
16.1.16.3 Recent developments
16.1.16.3.1 Product launches
16.1.16.3.2 Deals
16.1.16.3.3 Other developments
16.1.17 BPGBIO, INC.
16.1.17.1 Business overview
16.1.17.2 Products offered
16.1.17.3 Recent developments
16.1.17.3.1 Product launches
16.1.17.3.2 Deals
16.1.17.3.3 Other developments
16.1.18 EUROFINS DISCOVERY
16.1.18.1 Business overview
16.1.18.2 Products offered
16.1.18.3 Recent developments
16.1.18.3.1 Product launches
16.1.18.3.2 Deals
16.1.18.3.3 Expansions
16.2 OTHER PLAYERS
16.2.1 VERISIM LIFE
16.2.2 LIFEBIT BIOTECH INC.
16.2.3 VALO HEALTH
16.2.4 VERGE GENOMICS
16.2.5 LOGICA
16.2.6 AMERICAN CHEMICAL SOCIETY
16.2.7 AGANITHA AI INC.
17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW
4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION
4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING AND COUNTRY
4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT
4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing cross-industry collaborations and partnerships
5.2.1.2 Increasing need to reduce time and cost of drug discovery & development
5.2.1.3 Rising adoption of AI in precision medicine
5.2.1.4 Increasing investments in semiconductor chipsets
5.2.2 RESTRAINTS
5.2.2.1 High implementation costs
5.2.2.2 Data privacy risks and compliance challenges
5.2.3 OPPORTUNITIES
5.2.3.1 Rise of advanced analytics and predictive modeling
5.2.3.2 Surge in biotechnology investments
5.2.3.3 Innovations across healthcare, agriculture, and environmental science
5.2.4 CHALLENGES
5.2.4.1 Data quality and interpretability issues
5.2.4.2 Shortage of qualified experts and evolving regulatory challenges
5.3 UNMET NEEDS AND WHITE SPACES
5.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
5.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
6 INDUSTRY TRENDS
6.1 EVOLUTION OF AI IN BIOTECHNOLOGY
6.2 PORTER’S FIVE FORCES ANALYSIS
6.2.1 BARGAINING POWER OF SUPPLIERS
6.2.2 BARGAINING POWER OF BUYERS
6.2.3 THREAT OF SUBSTITUTES
6.2.4 THREAT OF NEW ENTRANTS
6.2.5 INTENSITY OF COMPETITIVE RIVALRY
6.3 MACROECONOMICS INDICATORS
6.3.1 INTRODUCTION
6.3.2 GDP TRENDS AND FORECAST
6.3.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
6.4 VALUE CHAIN ANALYSIS
6.5 ECOSYSTEM ANALYSIS
6.6 PRICING ANALYSIS
6.6.1 INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY OFFERING, BY KEY PLAYERS (2024)
6.6.2 INDICATIVE PRICING OF AI IN BIOTECHNOLOGY, BY REGION
6.7 KEY CONFERENCES AND EVENTS, 2025–2026
6.8 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6.9 INVESTMENT AND FUNDING SCENARIO
6.10 CASE STUDY ANALYSIS
6.10.1 CASE STUDY 1: RAPID TRAINING OF PROTEIN MODELS USING NVIDIA DGX CLOUD
6.10.2 CASE STUDY 2: IMPROVED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION
6.10.3 CASE STUDY 3: ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS
6.11 IMPACT OF 2025 US TARIFF ON AI IN BIOTECHNOLOGY MARKET
6.11.1 INTRODUCTION
6.11.2 KEY TARIFF RATES
6.11.3 PRICE IMPACT ANALYSIS
6.11.4 IMPACT ON COUNTRIES/REGIONS
6.11.4.1 North America
6.11.4.2 Europe
6.11.4.3 Asia Pacific
6.11.5 IMPACT ON END-USE INDUSTRIES
6.11.5.1 Pharmaceutical companies
6.11.5.2 Biotechnology companies
6.11.5.3 Research institutes and labs
6.11.5.4 Healthcare providers
6.11.5.5 Contract Research Organizations (CROs)
7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS
7.1 KEY EMERGING TECHNOLOGIES
7.1.1 NATURAL LANGUAGE PROCESSING (NLP)
7.1.2 PREDICTIVE ANALYTICS
7.2 COMPLEMENTARY TECHNOLOGIES
7.2.1 CLOUD COMPUTING
7.2.2 BIG DATA ANALYTICS
7.3 TECHNOLOGY/PRODUCT ROADMAP
7.4 PATENT ANALYSIS
7.4.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY
7.4.2 JURISDICTION AND TOP APPLICANT ANALYSIS
7.5 FUTURE APPLICATIONS
7.5.1 AI-ENABLED PRECISION DISCOVERY AND MULTI-OMICS INTEGRATION
7.5.2 GENERATIVE BIOLOGY AND AUTOMATED DESIGN OF MOLECULES, PROTEINS, AND GENETIC SYSTEMS
7.6 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET
7.6.1 INTRODUCTION
7.6.2 TOP USE CASES AND MARKET POTENTIAL
7.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
7.6.3.1 Drug discovery and development market
7.6.3.2 Genomics and bioinformatics market
7.6.3.3 Medical imaging & diagnostics market
7.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN AI IN BIOTECHNOLOGY MARKET
7.6.4.1 User readiness
7.6.4.1.1 Pharmaceutical companies
7.6.4.1.2 Biotechnology companies
7.6.4.2 Impact assessment
7.6.4.2.1 User A: Pharmaceutical companies
7.6.4.2.1.1 Implementation
7.6.4.2.1.2 Impact
7.6.4.2.2 User B: Biotechnology companies
7.6.4.2.2.1 Implementation
7.6.4.2.2.2 Impact
7.6.5 CASE STUDY ON AI/GENERATIVE AI IMPLEMENTATION
7.6.5.1 Case Study 1: Enhanced operations and revenue using AI-driven real-world data analytics
7.6.5.2 Case study 2: Advance AI-powered target discovery with proprietary AI platform
8 REGULATORY LANDSCAPE
8.1 REGIONAL REGULATIONS AND COMPLIANCE
8.1.1 NORTH AMERICA
8.1.2 EUROPE
8.1.3 ASIA PACIFIC
8.1.4 LATIN AMERICA
8.1.5 MIDDLE EAST & AFRICA
8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8.3 INDUSTRY STANDARDS
9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
9.1 DECISION-MAKING PROCESS
9.2 INFLUENCE OF STAKEHOLDERS AND BUYING CRITERIA
9.2.1 BUYING CRITERIA
9.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
9.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9.5 END-USER EXPECTATIONS
10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING
10.1 INTRODUCTION
10.2 END-TO-END SOLUTIONS
10.2.1 GROWING USE OF ADVANCED ALGORITHMS FOR BETTER PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH
10.3 NICHE SOLUTIONS
10.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION
10.4 TECHNOLOGIES
10.4.1 ADOPTION OF ADVANCED TECHNOLOGIES FOR DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH
10.5 SERVICES
10.5.1 CONSULTING SERVICES
10.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption
10.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
10.5.2.1 Increasing precision and efficiency in IT support services to boost demand
10.5.3 TRAINING & EDUCATION SERVICES
10.5.3.1 Need for skilled talent for better training & education services to drive market
10.5.4 POST-SALES & MAINTENANCE SERVICES
10.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market
11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION
11.1 INTRODUCTION
11.2 RESEARCH & DEVELOPMENT
11.2.1 DRUG DISCOVERY
11.2.1.1 Molecular design & optimization
11.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market
11.2.1.2 Biomarker discovery
11.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand
11.2.1.3 Structure-activity relationship (SAR) modeling
11.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth
11.2.2 CLINICAL DEVELOPMENT
11.2.2.1 Trial design
11.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market
11.2.2.2 Site selection
11.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth
11.2.2.3 Recruitment
11.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand
11.2.2.4 Clinical data assessment
11.2.2.4.1 Ability of clinical data assessment for efficient and accurate of data interpretation to propel market
11.2.2.5 Predictive toxicity & risk monitoring
11.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates
11.2.2.6 Monitoring & drug adherence
11.2.2.6.1 Enhanced patient compliance with monitoring and drug adherence to drive market
11.2.2.7 Real-world evidence (RWE) analysis
11.2.2.7.1 Enhanced safety monitoring and economic evaluation with RWE analysis to propel growth
11.3 REGULATORY COMPLIANCE
11.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH
11.4 MANUFACTURING & SUPPLY CHAIN
11.4.1 SUPPLY CHAIN PLANNING
11.4.1.1 Increasing demand for real-time data analytics to accelerate market growth
11.4.2 INVENTORY MANAGEMENT
11.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel market growth
11.4.3 LOGISTICS OPTIMIZATION
11.4.3.1 Ability of AI for increased collaboration and transparency in biotechnology logistics to aid growth
11.4.4 DEMAND FORECASTING
11.4.4.1 Ability to integrate data for a reliable demand forecast to fuel market growth
11.4.5 PREDICTIVE MAINTENANCE
11.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand
11.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS
11.5 LAUNCH & COMMERCIAL
11.5.1 LAUNCH COORDINATION
11.5.1.1 Increasing product launch success rates through predictive analytics to boost adoption
11.5.2 PATIENT ENGAGEMENT
11.5.2.1 Real-time patient feedback for better health outcomes to support growth
11.5.3 MARKETING OPERATIONS
11.5.3.1 Enhanced marketing performance with AI to boost market growth
11.5.4 PREDICTIVE PRICING
11.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption
11.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT
11.6.1 MEDICATION ADHERENCE
11.6.1.1 Growing demand for personalized treatment plans to drive market
11.6.2 ADVERSE EVENT REPORTING
11.6.2.1 Faster post-market surveillance and enhanced drug safety to drive demand
11.6.3 PATIENT MONITORING
11.6.3.1 Rise of remote healthcare solutions to boost market demand
11.6.4 COMPLIANCE MONITORING
11.6.4.1 Increasing complexity of regulatory requirements to drive adoption
11.6.5 PATIENT SUPPORT PROGRAMS
11.6.5.1 Growing interest in patient-centered care to support market growth
11.7 CORPORATE
11.7.1 RISK MANAGEMENT
11.7.1.1 Rising expenditure for drug development to support growth
11.7.2 COMPLIANCE MONITORING
11.7.2.1 Strict guidelines for complex regulatory landscapes to aid market growth
11.7.3 SALES FORCE OPTIMIZATION
11.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization
11.7.4 OTHER CORPORATE FUNCTIONS
12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE
12.1 INTRODUCTION
12.2 CLOUD-BASED SOLUTIONS
12.2.1 PUBLIC CLOUD
12.2.1.1 Need to reduce dependency on expensive on-premises infrastructure to boost demand
12.2.2 PRIVATE CLOUD
12.2.2.1 Need for enhanced security and data protection to propel market growth
12.2.3 MULTI-CLOUD
12.2.3.1 Enhanced flexibility and cost optimization to support market growth
12.2.4 HYBRID CLOUD
12.2.4.1 Cost efficiency and flexibility of hybrid cloud models to fuel market growth
12.3 ON-PREMISES SOLUTIONS
12.3.1 BETTER DATA SECURITY, PRIVACY, AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH
13 AI IN BIOTECHNOLOGY MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL COMPANIES
13.2.1 INNOVATION AND EFFICIENCY WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION
13.3 BIOTECHNOLOGY COMPANIES
13.3.1 ABILITY OF AI-DRIVEN INNOVATIONS FOR BETTER PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT MARKET GROWTH
13.4 RESEARCH INSTITUTES & LABS
13.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS
13.5 HEALTHCARE PROVIDERS
13.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION
13.6 CONTRACT RESEARCH ORGANIZATIONS
13.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH
14 AI IN BIOTECHNOLOGY MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 US to dominate North American AI in biotechnology market during study period
14.2.3 CANADA
14.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 GERMANY
14.3.2.1 Increased funding in startups to drive uptake of AI in biotechnology
14.3.3 UK
14.3.3.1 Increasing investments and government fund allocations to drive market
14.3.4 FRANCE
14.3.4.1 Government initiatives in France to support market growth
14.3.5 ITALY
14.3.5.1 Growing investments to create opportunities for market growth
14.3.6 SPAIN
14.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market
14.3.7 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 JAPAN
14.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive Japanese market
14.4.3 CHINA
14.4.3.1 Rising foreign investments in biotechnology and biopharmaceuticals to propel market growth
14.4.4 INDIA
14.4.4.1 Increasing number of startups and growing support from government to propel market growth
14.4.5 SOUTH KOREA
14.4.5.1 Significant advances in AI integration for R&D to fuel growth
14.4.6 AUSTRALIA
14.4.6.1 Accelerating AI adoption in Australia’s biotech sector to augment market growth
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Funding of biotech companies to drive Brazilian market growth
14.5.3 MEXICO
14.5.3.1 Investment inflows and strengthening AI-related education to spur market growth
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.2 GCC COUNTRIES
14.6.2.1 Increase in healthcare investments to support market growth
14.6.3 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET
15.3 REVENUE ANALYSIS, 2020–2024
15.4 MARKET SHARE ANALYSIS, 2024
15.4.1 RANKING OF KEY MARKET PLAYERS
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Component footprint
15.5.5.4 Function footprint
15.5.5.5 End-user footprint
15.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SME players
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & UPGRADES
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 NVIDIA CORPORATION
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 ILLUMINA, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 RECURSION
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.3.4 Other developments
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 SCHR?DINGER, INC.
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product upgrades
16.1.4.3.2 Deals
16.1.4.3.3 Other developments
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 BENEVOLENTAI
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Deals
16.1.5.3.2 Other developments
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 DATA4CURE, INC.
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Deals
16.1.7 QIAGEN
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches and enhancements
16.1.7.3.2 Deals
16.1.8 INSILICO MEDICINE
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product launches, approvals, and enhancements
16.1.8.3.2 Deals
16.1.8.3.3 Other developments
16.1.9 DNANEXUS, INC.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Deals
16.1.9.3.2 Other developments
16.1.10 TEMPUS
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product approvals
16.1.10.3.2 Deals
16.1.10.3.3 Other developments
16.1.11 SOPHIA GENETICS
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches
16.1.11.3.2 Deals
16.1.11.3.3 Other developments
16.1.12 PREDICTIVE ONCOLOGY
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches
16.1.12.3.2 Deals
16.1.12.3.3 Expansions
16.1.13 DEEP GENOMICS
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Product launches
16.1.14 NUMEDII, INC.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.15 XTALPI INC.
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Deals
16.1.16 IKTOS
16.1.16.1 Business overview
16.1.16.2 Products offered
16.1.16.3 Recent developments
16.1.16.3.1 Product launches
16.1.16.3.2 Deals
16.1.16.3.3 Other developments
16.1.17 BPGBIO, INC.
16.1.17.1 Business overview
16.1.17.2 Products offered
16.1.17.3 Recent developments
16.1.17.3.1 Product launches
16.1.17.3.2 Deals
16.1.17.3.3 Other developments
16.1.18 EUROFINS DISCOVERY
16.1.18.1 Business overview
16.1.18.2 Products offered
16.1.18.3 Recent developments
16.1.18.3.1 Product launches
16.1.18.3.2 Deals
16.1.18.3.3 Expansions
16.2 OTHER PLAYERS
16.2.1 VERISIM LIFE
16.2.2 LIFEBIT BIOTECH INC.
16.2.3 VALO HEALTH
16.2.4 VERGE GENOMICS
16.2.5 LOGICA
16.2.6 AMERICAN CHEMICAL SOCIETY
16.2.7 AGANITHA AI INC.
17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 AI IN BIOTECHNOLOGY MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 3 AI IN BIOTECHNOLOGY MARKET: RESEARCH ASSUMPTIONS
TABLE 4 AI IN BIOTECHNOLOGY MARKET: RISK ASSESSMENT
TABLE 5 AI IN BIOTECHNOLOGY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 6 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET, 2022?2025
TABLE 7 TABLE AI IN BIOTECHNOLOGY MARKET: UNMET NEEDS
TABLE 8 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 9 FIGURE 5 AI IN BIOTECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY OFFERINGS,BY KEY PLAYER, 2024 (USD)
TABLE 11 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY REGION (2024)
TABLE 12 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 13 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, 2015–2025
TABLE 15 TABLE AI IN BIOTECHNOLOGY MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022–2025
TABLE 16 REGULATORY SCENARIO OF NORTH AMERICA
TABLE 17 REGULATORY SCENARIO OF EUROPE
TABLE 18 REGULATORY SCENARIO OF ASIA PACIFIC
TABLE 19 REGULATORY SCENARIO OF LATIN AMERICA
TABLE 20 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
TABLE 21 TABLE NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 TABLE EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 TABLE ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 TABLE REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 27 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET
TABLE 28 TABLE END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET
TABLE 29 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 30 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,2023–2029 (USD MILLION)
TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,2030–2035 (USD MILLION)
TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,2023–2029 (USD MILLION)
TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,2030–2035 (USD MILLION)
TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,2023–2029 (USD MILLION)
TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,2030–2035 (USD MILLION)
TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,2023–2029 (USD MILLION)
TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,2030–2035 (USD MILLION)
TABLE 39 CONSULTING SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 40 CONSULTING SERVICES MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 41 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 42 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 43 TRAINING AND EDUCATION SERVICES MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 44 TRAINING AND EDUCATION SERVICES MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 45 POST-SALES AND MAINTENANCE SERVICES MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES AND MAINTENANCE SERVICES, BY REGION, 2030–2035 (USD MILLION)
TABLE 47 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 48 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2023–2029 (USD MILLION)
TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2030–2035 (USD MILLION)
TABLE 53 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY
TABLE 54 DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 55 DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 56 DRUG DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 57 DRUG DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 58 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 59 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 60 BIOMARKER DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 61 BIOMARKER DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 62 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 63 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 64 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 65 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 66 CLINICAL DEVELOPMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 67 CLINICAL DEVELOPMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 68 TRIAL DESIGN MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 69 TRIAL DESIGN MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 70 SITE SELECTION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 71 SITE SELECTION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 72 RECRUITMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 73 RECRUITMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 74 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 75 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 76 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 77 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 78 MONITORING & DRUG ADHERENCE MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 79 MONITORING & DRUG ADHERENCE MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 80 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 81 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023–2029 (USD MILLION)
TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2030–2035 (USD MILLION)
TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 85 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 86 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY REGION, 2023–2029 (USD MILLION)
TABLE 87 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY REGION, 2030–2035 (USD MILLION)
TABLE 88 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 89 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 90 INVENTORY MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 91 INVENTORY MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 92 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 93 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 94 DEMAND FORECASTING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 95 DEMAND FORECASTING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 96 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 97 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 98 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 99 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 100 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,2023–2029 (USD MILLION)
TABLE 101 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,2030–2035 (USD MILLION)
TABLE 102 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,2023–2029 (USD MILLION)
TABLE 103 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,2030–2035 (USD MILLION)
TABLE 104 LAUNCH COORDINATION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 105 LAUNCH COORDINATION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 106 PATIENT ENGAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 107 PATIENT ENGAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 108 MARKETING OPERATIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 109 MARKETING OPERATIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 110 PREDICTIVE PRICING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 111 PREDICTIVE PRICING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 112 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 113 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 114 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2023–2029 (USD MILLION)
TABLE 115 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2030–2035 (USD MILLION)
TABLE 116 MEDICATION ADHERENCE MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 117 MEDICATION ADHERENCE MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 118 ADVERSE EVENT REPORTING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 119 ADVERSE EVENT REPORTING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 120 PATIENT MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 121 PATIENT MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 122 COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 123 COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 124 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 125 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 126 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 127 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 128 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,2023–2029 (USD MILLION)
TABLE 129 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,2030–2035 (USD MILLION)
TABLE 130 RISK MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 131 RISK MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 132 COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 133 COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 134 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 135 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 136 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 137 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 138 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 139 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 140 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,2023–2029 (USD MILLION)
TABLE 141 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,2030–2035 (USD MILLION)
TABLE 142 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
TABLE 143 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
TABLE 144 PUBLIC CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 145 PUBLIC CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 146 PRIVATE CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 147 PRIVATE CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 148 MULTI CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 149 MULTI CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 150 HYBRID CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 151 HYBRID CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 152 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
TABLE 153 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
TABLE 154 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
TABLE 155 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
TABLE 156 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2029 (USD MILLION)
TABLE 157 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2030–2035 (USD MILLION)
TABLE 158 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2029 (USD MILLION)
TABLE 159 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2030–2035 (USD MILLION)
TABLE 160 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2023–2029 (USD MILLION)
TABLE 161 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2030–2035 (USD MILLION)
TABLE 162 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2029 (USD MILLION)
TABLE 163 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2030–2035 (USD MILLION)
TABLE 164 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,BY REGION, 2023–2029 (USD MILLION)
TABLE 165 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,BY REGION, 2030–2035 (USD MILLION)
TABLE 166 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 167 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 168 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2023–2029 (USD MILLION)
TABLE 169 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2030–2035 (USD MILLION)
TABLE 170 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 171 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 172 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 174 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 175 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 176 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 177 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 178 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,2023–2029 (USD MILLION)
TABLE 179 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,2030–2035 (USD MILLION)
TABLE 180 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,2023–2029 (USD MILLION)
TABLE 181 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,2030–2035 (USD MILLION)
TABLE 182 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 183 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 184 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 185 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 186 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 187 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 188 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
TABLE 189 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
TABLE 190 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 191 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
TABLE 192 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 193 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 194 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 196 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 197 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 198 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 199 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 200 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 201 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 202 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 203 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 204 US: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 205 US: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 206 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 207 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 208 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2023–2029 (USD MILLION)
TABLE 209 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2030–2035 (USD MILLION)
TABLE 210 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 211 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 212 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 213 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 214 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 215 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 216 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 217 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 218 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 219 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 220 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
TABLE 221 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
TABLE 222 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 223 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 224 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 225 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 226 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 227 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 228 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 229 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2030–2035 (USD MILLION)
TABLE 230 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 231 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 232 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 233 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 234 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 235 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 236 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 237 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 238 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 239 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 240 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 241 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 242 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 243 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 244 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2023–2029 (USD MILLION)
TABLE 245 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2030–2035 (USD MILLION)
TABLE 246 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 247 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 248 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2023–2029 (USD MILLION)
TABLE 249 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2030–2035 (USD MILLION)
TABLE 250 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 251 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 252 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 253 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 254 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 255 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 256 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 257 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2030–2035 (USD MILLION)
TABLE 258 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 259 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 260 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 261 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 262 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 263 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 264 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 265 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 266 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 267 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 268 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 269 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 270 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 271 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 272 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2023–2029 (USD MILLION)
TABLE 273 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2030–2035 (USD MILLION)
TABLE 274 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 275 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 276 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 277 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 278 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 279 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 280 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 281 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 282 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 283 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 284 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 285 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 286 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,2023–2029 (USD MILLION)
TABLE 287 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,2030–2035 (USD MILLION)
TABLE 288 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 289 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 290 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,BY TYPE, 2023–2029 (USD MILLION)
TABLE 291 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,BY TYPE, 2030–2035 (USD MILLION)
TABLE 292 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 293 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 294 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 295 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 296 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 297 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 298 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2023–2029 (USD MILLION)
TABLE 299 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2030–2035 (USD MILLION)
TABLE 300 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 301 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 302 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 303 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 304 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 305 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 306 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 307 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 308 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 309 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 310 UK: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 311 UK: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 312 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 313 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 314 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2023–2029 (USD MILLION)
TABLE 315 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2030–2035 (USD MILLION)
TABLE 316 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 317 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 318 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 319 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 320 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 321 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 322 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 323 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 324 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 325 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 326 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
TABLE 327 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
TABLE 328 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 329 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 330 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 331 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 332 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 333 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 334 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 335 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2030–2035 (USD MILLION)
TABLE 336 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 337 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 338 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 339 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 340 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 341 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 342 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 343 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 344 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 345 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 346 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 347 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 348 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 349 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 350 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 351 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 352 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 353 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 354 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 355 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 356 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 357 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 358 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 359 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 360 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 361 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 362 ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 363 ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 364 ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 365 ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 366 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2023–2029 (USD MILLION)
TABLE 367 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2030–2035 (USD MILLION)
TABLE 1 AI IN BIOTECHNOLOGY MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 3 AI IN BIOTECHNOLOGY MARKET: RESEARCH ASSUMPTIONS
TABLE 4 AI IN BIOTECHNOLOGY MARKET: RISK ASSESSMENT
TABLE 5 AI IN BIOTECHNOLOGY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 6 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET, 2022?2025
TABLE 7 TABLE AI IN BIOTECHNOLOGY MARKET: UNMET NEEDS
TABLE 8 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 9 FIGURE 5 AI IN BIOTECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY OFFERINGS,BY KEY PLAYER, 2024 (USD)
TABLE 11 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY REGION (2024)
TABLE 12 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 13 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, 2015–2025
TABLE 15 TABLE AI IN BIOTECHNOLOGY MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022–2025
TABLE 16 REGULATORY SCENARIO OF NORTH AMERICA
TABLE 17 REGULATORY SCENARIO OF EUROPE
TABLE 18 REGULATORY SCENARIO OF ASIA PACIFIC
TABLE 19 REGULATORY SCENARIO OF LATIN AMERICA
TABLE 20 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
TABLE 21 TABLE NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 TABLE EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 TABLE ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 TABLE REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 27 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET
TABLE 28 TABLE END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET
TABLE 29 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 30 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,2023–2029 (USD MILLION)
TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,2030–2035 (USD MILLION)
TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,2023–2029 (USD MILLION)
TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,2030–2035 (USD MILLION)
TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,2023–2029 (USD MILLION)
TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,2030–2035 (USD MILLION)
TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,2023–2029 (USD MILLION)
TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,2030–2035 (USD MILLION)
TABLE 39 CONSULTING SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 40 CONSULTING SERVICES MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 41 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 42 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 43 TRAINING AND EDUCATION SERVICES MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 44 TRAINING AND EDUCATION SERVICES MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 45 POST-SALES AND MAINTENANCE SERVICES MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES AND MAINTENANCE SERVICES, BY REGION, 2030–2035 (USD MILLION)
TABLE 47 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 48 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2023–2029 (USD MILLION)
TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2030–2035 (USD MILLION)
TABLE 53 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY
TABLE 54 DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 55 DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 56 DRUG DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 57 DRUG DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 58 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 59 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 60 BIOMARKER DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 61 BIOMARKER DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 62 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 63 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 64 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 65 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 66 CLINICAL DEVELOPMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 67 CLINICAL DEVELOPMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 68 TRIAL DESIGN MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 69 TRIAL DESIGN MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 70 SITE SELECTION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 71 SITE SELECTION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 72 RECRUITMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 73 RECRUITMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 74 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 75 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 76 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 77 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 78 MONITORING & DRUG ADHERENCE MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 79 MONITORING & DRUG ADHERENCE MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 80 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,2023–2029 (USD MILLION)
TABLE 81 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,2030–2035 (USD MILLION)
TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023–2029 (USD MILLION)
TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2030–2035 (USD MILLION)
TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 85 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 86 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY REGION, 2023–2029 (USD MILLION)
TABLE 87 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY REGION, 2030–2035 (USD MILLION)
TABLE 88 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 89 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 90 INVENTORY MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 91 INVENTORY MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 92 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 93 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 94 DEMAND FORECASTING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 95 DEMAND FORECASTING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 96 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 97 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 98 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 99 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 100 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,2023–2029 (USD MILLION)
TABLE 101 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,2030–2035 (USD MILLION)
TABLE 102 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,2023–2029 (USD MILLION)
TABLE 103 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,2030–2035 (USD MILLION)
TABLE 104 LAUNCH COORDINATION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 105 LAUNCH COORDINATION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 106 PATIENT ENGAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 107 PATIENT ENGAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 108 MARKETING OPERATIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 109 MARKETING OPERATIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 110 PREDICTIVE PRICING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 111 PREDICTIVE PRICING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 112 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 113 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 114 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2023–2029 (USD MILLION)
TABLE 115 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2030–2035 (USD MILLION)
TABLE 116 MEDICATION ADHERENCE MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 117 MEDICATION ADHERENCE MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 118 ADVERSE EVENT REPORTING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 119 ADVERSE EVENT REPORTING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 120 PATIENT MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 121 PATIENT MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 122 COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 123 COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 124 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 125 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 126 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 127 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 128 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,2023–2029 (USD MILLION)
TABLE 129 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,2030–2035 (USD MILLION)
TABLE 130 RISK MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 131 RISK MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 132 COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 133 COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 134 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 135 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 136 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 137 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 138 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 139 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 140 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,2023–2029 (USD MILLION)
TABLE 141 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,2030–2035 (USD MILLION)
TABLE 142 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
TABLE 143 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
TABLE 144 PUBLIC CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 145 PUBLIC CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 146 PRIVATE CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 147 PRIVATE CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 148 MULTI CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 149 MULTI CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 150 HYBRID CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 151 HYBRID CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 152 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
TABLE 153 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
TABLE 154 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
TABLE 155 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
TABLE 156 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2029 (USD MILLION)
TABLE 157 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2030–2035 (USD MILLION)
TABLE 158 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2029 (USD MILLION)
TABLE 159 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2030–2035 (USD MILLION)
TABLE 160 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2023–2029 (USD MILLION)
TABLE 161 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2030–2035 (USD MILLION)
TABLE 162 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2029 (USD MILLION)
TABLE 163 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2030–2035 (USD MILLION)
TABLE 164 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,BY REGION, 2023–2029 (USD MILLION)
TABLE 165 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,BY REGION, 2030–2035 (USD MILLION)
TABLE 166 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023–2029 (USD MILLION)
TABLE 167 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030–2035 (USD MILLION)
TABLE 168 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2023–2029 (USD MILLION)
TABLE 169 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2030–2035 (USD MILLION)
TABLE 170 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 171 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 172 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 174 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 175 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 176 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 177 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 178 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,2023–2029 (USD MILLION)
TABLE 179 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,2030–2035 (USD MILLION)
TABLE 180 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,2023–2029 (USD MILLION)
TABLE 181 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,2030–2035 (USD MILLION)
TABLE 182 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 183 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 184 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 185 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 186 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 187 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 188 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
TABLE 189 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
TABLE 190 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 191 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
TABLE 192 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 193 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 194 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 196 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 197 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 198 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 199 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 200 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 201 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 202 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 203 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 204 US: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 205 US: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 206 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 207 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 208 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2023–2029 (USD MILLION)
TABLE 209 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2030–2035 (USD MILLION)
TABLE 210 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 211 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 212 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 213 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 214 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 215 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 216 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 217 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 218 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 219 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 220 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
TABLE 221 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
TABLE 222 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 223 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 224 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 225 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 226 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 227 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 228 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 229 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2030–2035 (USD MILLION)
TABLE 230 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 231 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 232 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 233 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 234 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 235 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 236 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 237 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 238 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 239 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 240 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 241 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 242 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 243 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 244 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2023–2029 (USD MILLION)
TABLE 245 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2030–2035 (USD MILLION)
TABLE 246 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 247 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 248 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2023–2029 (USD MILLION)
TABLE 249 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,2030–2035 (USD MILLION)
TABLE 250 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 251 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 252 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 253 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 254 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 255 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 256 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 257 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2030–2035 (USD MILLION)
TABLE 258 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 259 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 260 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 261 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 262 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 263 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 264 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 265 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 266 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 267 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 268 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 269 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 270 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 271 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 272 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2023–2029 (USD MILLION)
TABLE 273 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2030–2035 (USD MILLION)
TABLE 274 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 275 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 276 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 277 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 278 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 279 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 280 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 281 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 282 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 283 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 284 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 285 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 286 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,2023–2029 (USD MILLION)
TABLE 287 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,2030–2035 (USD MILLION)
TABLE 288 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 289 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 290 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,BY TYPE, 2023–2029 (USD MILLION)
TABLE 291 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,BY TYPE, 2030–2035 (USD MILLION)
TABLE 292 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 293 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 294 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 295 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 296 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 297 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 298 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2023–2029 (USD MILLION)
TABLE 299 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,BY TYPE, 2030–2035 (USD MILLION)
TABLE 300 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 301 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 302 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 303 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 304 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 305 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 306 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 307 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 308 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 309 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 310 UK: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 311 UK: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 312 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 313 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 314 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2023–2029 (USD MILLION)
TABLE 315 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2030–2035 (USD MILLION)
TABLE 316 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 317 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 318 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 319 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 320 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 321 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 322 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 323 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 324 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 325 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 326 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
TABLE 327 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
TABLE 328 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2023–2029 (USD MILLION)
TABLE 329 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,2030–2035 (USD MILLION)
TABLE 330 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 331 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 332 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2023–2029 (USD MILLION)
TABLE 333 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2030–2035 (USD MILLION)
TABLE 334 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2023–2029 (USD MILLION)
TABLE 335 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,BY TYPE, 2030–2035 (USD MILLION)
TABLE 336 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 337 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 338 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 339 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 340 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
TABLE 341 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
TABLE 342 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
TABLE 343 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
TABLE 344 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 345 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 346 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2023–2029 (USD MILLION)
TABLE 347 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,2030–2035 (USD MILLION)
TABLE 348 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2023–2029 (USD MILLION)
TABLE 349 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2030–2035 (USD MILLION)
TABLE 350 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 351 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
TABLE 352 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2023–2029 (USD MILLION)
TABLE 353 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,2030–2035 (USD MILLION)
TABLE 354 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
TABLE 355 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
TABLE 356 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2023–2029 (USD MILLION)
TABLE 357 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,2030–2035 (USD MILLION)
TABLE 358 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
TABLE 359 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
TABLE 360 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
TABLE 361 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
TABLE 362 ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 363 ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 364 ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 365 ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
TABLE 366 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2023–2029 (USD MILLION)
TABLE 367 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,BY TYPE, 2030–2035 (USD MILLION)
LIST OF FIGURES
FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 AI IN BIOTECHNOLOGY MARKET: YEARS CONSIDERED
FIGURE 3 RESEARCH DESIGN
FIGURE 4 PRIMARY SOURCES
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY COMPANY, DESIGNATION, AND REGION
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
FIGURE 8 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 10 DATA TRIANGULATION
FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2025 VS. 2035 (USD MILLION)
FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2025 VS. 2035 (USD MILLION)
FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2025 VS. 2035 (USD MILLION)
FIGURE 14 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION)
FIGURE 15 AI IN BIOTECHNOLOGY MARKET: REGIONAL SNAPSHOT
FIGURE 16 FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT FUNDING TO DRIVE MARKET
FIGURE 17 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING STUDY PERIOD
FIGURE 18 END-TO-END SOLUTIONS AND US COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024
FIGURE 19 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES FROM 2025 TO 2035
FIGURE 21 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET
FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 24 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
FIGURE 25 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
FIGURE 26 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 27 AI IN BIOTECHNOLOGY MARKET: INVESTMENT AND FUNDING SCENARIO
FIGURE 28 AI IN BIOTECHNOLOGY MARKET: PATENT PUBLICATION TRENDS, 2015–2025
FIGURE 29 JURISDICTION AND TOP APPLICANT ANALYSIS, 2015–2025
FIGURE 30 AI IN BIOTECHNOLOGY MARKET: PATENT ANALYSIS, JANUARY 2015–JANUARY 2025
FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS
FIGURE 33 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 34 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS, 2019–2023
FIGURE 35 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
FIGURE 36 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2020–2024 (USD BILLION)
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)
FIGURE 39 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)
FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT
FIGURE 42 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2024
FIGURE 43 EV/EBITDA OF KEY VENDORS
FIGURE 44 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF AI IN BIOTECHNOLOGY SOLUTION VENDORS
FIGURE 45 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 46 NVIDIA CORPORATION: COMPANY SNAPSHOT
FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 48 RECURSION: COMPANY SNAPSHOT
FIGURE 49 SCHR?DINGER, INC.: COMPANY SNAPSHOT
FIGURE 50 BENEVOLENTAI: COMPANY SNAPSHOT
FIGURE 51 QIAGEN: COMPANY SNAPSHOT
FIGURE 52 SOPHIA GENETICS: COMPANY SNAPSHOT
FIGURE 53 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT
FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT
FIGURE 55 EUROFINS DISCOVERY: COMPANY SNAPSHOT
FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 AI IN BIOTECHNOLOGY MARKET: YEARS CONSIDERED
FIGURE 3 RESEARCH DESIGN
FIGURE 4 PRIMARY SOURCES
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY COMPANY, DESIGNATION, AND REGION
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
FIGURE 8 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 10 DATA TRIANGULATION
FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2025 VS. 2035 (USD MILLION)
FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2025 VS. 2035 (USD MILLION)
FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2025 VS. 2035 (USD MILLION)
FIGURE 14 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION)
FIGURE 15 AI IN BIOTECHNOLOGY MARKET: REGIONAL SNAPSHOT
FIGURE 16 FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT FUNDING TO DRIVE MARKET
FIGURE 17 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING STUDY PERIOD
FIGURE 18 END-TO-END SOLUTIONS AND US COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024
FIGURE 19 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES FROM 2025 TO 2035
FIGURE 21 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET
FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 24 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
FIGURE 25 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
FIGURE 26 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 27 AI IN BIOTECHNOLOGY MARKET: INVESTMENT AND FUNDING SCENARIO
FIGURE 28 AI IN BIOTECHNOLOGY MARKET: PATENT PUBLICATION TRENDS, 2015–2025
FIGURE 29 JURISDICTION AND TOP APPLICANT ANALYSIS, 2015–2025
FIGURE 30 AI IN BIOTECHNOLOGY MARKET: PATENT ANALYSIS, JANUARY 2015–JANUARY 2025
FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS
FIGURE 33 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 34 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS, 2019–2023
FIGURE 35 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
FIGURE 36 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2020–2024 (USD BILLION)
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)
FIGURE 39 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)
FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT
FIGURE 42 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2024
FIGURE 43 EV/EBITDA OF KEY VENDORS
FIGURE 44 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF AI IN BIOTECHNOLOGY SOLUTION VENDORS
FIGURE 45 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 46 NVIDIA CORPORATION: COMPANY SNAPSHOT
FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 48 RECURSION: COMPANY SNAPSHOT
FIGURE 49 SCHR?DINGER, INC.: COMPANY SNAPSHOT
FIGURE 50 BENEVOLENTAI: COMPANY SNAPSHOT
FIGURE 51 QIAGEN: COMPANY SNAPSHOT
FIGURE 52 SOPHIA GENETICS: COMPANY SNAPSHOT
FIGURE 53 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT
FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT
FIGURE 55 EUROFINS DISCOVERY: COMPANY SNAPSHOT
